{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T21:08:52Z","timestamp":1775250532398,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,12]],"date-time":"2018-10-12T00:00:00Z","timestamp":1539302400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12879-018-3400-6","type":"journal-article","created":{"date-parts":[[2018,10,12]],"date-time":"2018-10-12T12:08:19Z","timestamp":1539346099000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Virologic suppression in response to antiretroviral therapy despite extensive resistance within HIV-1 reverse transcriptase after the first virologic failure"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2897-8938","authenticated-orcid":false,"given":"Marta Iglis","family":"Oliveira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5743-7770","authenticated-orcid":false,"given":"Valter","family":"Rom\u00e3o de Souza Junior","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Fernanda de Lacerda Vidal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulo","family":"S\u00e9rgio Ramos de Ara\u00fajo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,12]]},"reference":[{"key":"3400_CR1","unstructured":"1 Joint United Nations Programme on HIV\/AIDS. Global AIDS Update. 2016. http:\/\/www.unaids.org\/en\/topic\/treatment . (Accessed Dec 20, 2017)."},{"key":"3400_CR2","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1056\/NEJMoa062360","volume":"355","author":"WM El- Sadr","year":"2006","unstructured":"Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El- Sadr WM, Lundgren J, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283\u201396.","journal-title":"N Engl J Med"},{"issue":"2","key":"3400_CR3","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1001\/jama.2016.5148","volume":"316","author":"AJ Rodger","year":"2016","unstructured":"Rodger AJ, Cambiano V, Bruun T, et al. PARTNER study group. Sexual activity without condoms and risk of hiv transmission in serodifferent couples when the HIV- positive partner is using suppressive antiretroviral therapy. JAMA. 2016;316(2):171\u201381.","journal-title":"JAMA"},{"key":"3400_CR4","unstructured":"World Health Organization. HIV drug resistance report 2017. ( https:\/\/www.who.int\/hiv\/pub\/drugresistance\/hivdr-report-2017\/en\/ )."},{"issue":"8","key":"3400_CR5","doi-asserted-by":"publisher","first-page":"e1001290","DOI":"10.1371\/journal.pmed.1001290","volume":"9","author":"Thomas B. Campbell","year":"2012","unstructured":"Campbell TB, Smeaton LM, Kumarasamy N, et al. Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings. PLoS Med 2012; 9:e1001290. [sPubMed: 22936892].","journal-title":"PLoS Medicine"},{"issue":"3","key":"3400_CR6","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1097\/QAI.0000000000000724","volume":"70","author":"Myres Tilghman","year":"2015","unstructured":"Tilghman M, Tsai D, Buene TP, et al. Pooled nucleic acid testing to detect antiretroviral treatment failure in HIV-infected patients in Mozambique. J Acquir Immune Defic Syndr. 2015;70:256\u2013261. [PubMed: 26135327].","journal-title":"JAIDS Journal of Acquired Immune Deficiency Syndromes"},{"key":"3400_CR7","unstructured":"Joint United Nations Programme on HIV\/AIDS. Global AIDS Update. 2016. In:. Accessed 20 Dec 2017."},{"key":"3400_CR8","unstructured":"Brasil. Protocolo Cl\u00ednico e Diretrizes Terap\u00eauticas para Manejo da Infec\u00e7\u00e3o pelo HIV em Adultos. Data de publica\u00e7\u00e3o: 03\/10\/2013. Data \u00faltima atualiza\u00e7\u00e3o: 31\/07\/2015. Available at https:\/\/www.aids.gov.br\/tags\/publicacoes\/protocolo-clinico-e-diretrizes-terapeuticas . (Accessed 20 Aug 2017)."},{"key":"3400_CR9","unstructured":"Brasil. Protocolo Cl\u00ednico e Diretrizes Terap\u00eauticas para Manejo da Infec\u00e7\u00e3o pelo HIVem Adultos. Data de publica\u00e7\u00e3o: 2017. Available at www.aids.gov.br\/tags\/publicacoes\/protocolo-clinico-e-diretrizes-terapeuticas . (Accessed 01 Dec 2017)."},{"issue":"2","key":"3400_CR10","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1089\/aid.2017.0052","volume":"34","author":"Elaine Monteiro Matsuda","year":"2018","unstructured":"Matsuda EM, Coelho LP, Romero G, et al. High prevalence of drug resis- tance mutations among patients failing first-line antiretroviral therapy and predictors of virological response 24 weeks after switch to second-line therapy in S\u00e3o Paulo state, Brazil. AIDS Res Hum Retroviruses. 2017;34(2):1\u201327. http:\/\/doi.org\/10.1089\/aid.2017.0052 .","journal-title":"AIDS Research and Human Retroviruses"},{"issue":"4","key":"3400_CR11","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.bjid.2016.03.010","volume":"20","author":"C Brites","year":"2016","unstructured":"Brites C, Pinto-Neto L, Medeiros M, et al. Extensive variation in drug-resistance mutational profile of Brazilian patients failing antiretroviral therapy in five large Brazilian cities. Braz J Infect Dis. 2016;20(4):323\u20139.","journal-title":"Braz J Infect Dis"},{"key":"3400_CR12","unstructured":"World Health Organization. Consolidated Guidelines on the use of antiretrovi- ral drugs for treating and preventing HIV infection. https:\/\/www.who.int\/hiv\/pub\/arv\/treatment-monitoring-info-2017\/en\/ (Accessed 20 Dec 2017)."},{"key":"3400_CR13","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1016\/S0140-6736(13)61164-2","volume":"381","author":"MA Boyd","year":"2013","unstructured":"Boyd MA, Kumarasamy N, Moore CL, et al. for the second-line study group. Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study. Lancet. 2013;381:2091\u20139.","journal-title":"Lancet"},{"issue":"3","key":"3400_CR14","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1056\/NEJMoa1311274","volume":"371","author":"NI Paton","year":"2014","unstructured":"Paton NI, Kityo C, Hoppe A, et al. EARNEST trial team. Assessment of second- line antiretroviral regimens for HIV therapy in Africa. N Engl J Med. 2014;371(3):234\u201347.","journal-title":"N Engl J Med"},{"key":"3400_CR15","doi-asserted-by":"publisher","first-page":"e247","DOI":"10.1016\/S2352-3018(16)30011-X","volume":"3","author":"AM La Rosa","year":"2016","unstructured":"La Rosa AM, Harrison LJ, Taiwo B, et al. Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non- inferiority study. Lancet HIV. 2016;3:e247\u201358.","journal-title":"Lancet HIV"},{"key":"3400_CR16","unstructured":"2017 Resistance Mutations Update. Volume 24, Issue 4, Dec. 2016\/January 2017. Available at https:\/\/www.iasusa.org\/sites\/default\/files\/uploads\/2017hiv-muta-article.pdf . Accessed in 01\/20\/2017."},{"key":"3400_CR17","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1590\/S0074-02762007005000109","volume":"102","author":"AM Cavalcanti","year":"2007","unstructured":"Cavalcanti AM, Lacerda HR, Brito AM, et al. Antiretroviral resistance in individuals presenting therapeutic failure and subtypes of the human immunodeficiency virus type 1 in the northeast region of Brazil. Mem Inst Oswaldo Cruz. 2007;102:785\u201392.","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"3400_CR18","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1590\/S0074-02762007000600006","volume":"102","author":"HR Lacerda","year":"2007","unstructured":"Lacerda HR, Medeiros LB, Cavalcanti AM, et al. Comparison of the epidemi- ology, profile of mutations, and clinical response to antiretrovirals among subtypes B and F of the human immunodeficiency virus type 1. Mem Inst Oswaldo Cruz. 2007;102:693\u20139.","journal-title":"Mem Inst Oswaldo Cruz"},{"issue":"5","key":"3400_CR19","doi-asserted-by":"publisher","first-page":"e0155854","DOI":"10.1371\/journal.pone.0155854","volume":"11","author":"K Lima","year":"2016","unstructured":"Lima K, de Souza Leal \u00c9, AMS C, Salustiano DM, de Medeiros LB, da Silva SP, et al. Epidemiological, Clinical and Antiretroviral Susceptibility Characterization of Human Immunodeficiency Virus Subtypes B and Non-B in Pernambuco, Northeast Brazil. PLoS One. 2016;11(5):e0155854.","journal-title":"PLoS One"},{"issue":"17","key":"3400_CR20","first-page":"1","volume":"3018","author":"S Kanters","year":"2017","unstructured":"Kanters S, Socias ME, Paton NI, et al. Comparative efficacy and safety of second- line antiretroviral therapy for treatment of HIV\/AIDS: a systematic review and network meta-analysis. The Lancet HIV. 2017;3018(17):1\u20139.","journal-title":"The Lancet HIV"},{"key":"3400_CR21","doi-asserted-by":"publisher","first-page":"12341","DOI":"10.1128\/JVI.01681-15","volume":"89","author":"T Gr\u00e4f","year":"2015","unstructured":"Gr\u00e4f T, Vrancken B, Maletich Junqueira D, et al. Contribution of epidemiological predictors in unraveling the phylogeographic history of HIV-1 subtype C in Brazil. J Virol. 2015;89:12341\u20138.","journal-title":"J Virol"},{"issue":"1","key":"3400_CR22","doi-asserted-by":"publisher","first-page":"e87622","DOI":"10.1371\/journal.pone.0087622","volume":"9","author":"CA Velasco-de-Castro","year":"2014","unstructured":"Velasco-de-Castro CA, Grinsztejn B, Veloso VG, et al. HIV-1 diversity and drug resistance mutations among people seeking HIV diagnosis in voluntary counseling and testing sites in Rio de Janeiro, Brazil. PLoS One. 2014;9(1):e87622.","journal-title":"PLoS One"},{"issue":"5","key":"3400_CR23","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1086\/381784","volume":"189","author":"MD Miller","year":"2004","unstructured":"Miller MD, Margot N, Lu B, Zhong L, et al. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral- experienced patients. J Infect Dis. 2004;189(5):837\u201346.","journal-title":"J Infect Dis"},{"issue":"5","key":"3400_CR24","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1128\/AAC.05487-11","volume":"56","author":"GL Melikian","year":"2012","unstructured":"Melikian GL, Rhee SY, Taylor J, et al. Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibility. Antimicrob Agents Chemother. 2012;56(5):2305\u201313.","journal-title":"Antimicrob Agents Chemother"},{"key":"3400_CR25","first-page":"738528e","volume":"2015","author":"CA Lopes","year":"2015","unstructured":"Lopes CA, Soares MA, Falci DR, Sprinz E. The evolving genotypic profile of HIV- 1 mutations related to antiretroviral treatment in the north region of Brazil. Biomed Res Int. 2015;2015:738528e.","journal-title":"Biomed Res Int"},{"issue":"11","key":"3400_CR26","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1093\/cid\/cis254","volume":"54","author":"RL Hamers","year":"2012","unstructured":"Hamers RL, Sigaloff KC, Wensing AM, et al. PharmAccess African studies to evaluate resistance (PASER). Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. Clin Infect Dis. 2012;54(11):1660\u20139.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"3400_CR27","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1089\/aid.2016.0070","volume":"33","author":"S Sivamalar","year":"2017","unstructured":"Sivamalar S, Dinesha TR, Gomathi S, et al. Accumulation of HIV-1 drug resistance mutations after first-line immunological failure to evaluate the options of recycling NRTI drugs in second-line treatment: a study from South India. AIDS Res Hum Retrovir. 2017;33(3):271\u20134.","journal-title":"AIDS Res Hum Retrovir"},{"key":"3400_CR28","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S1473-3099(15)00536-8","volume":"16","author":"The TenoRes Study Group","year":"2016","unstructured":"The TenoRes Study Group. Global epidemiology of drug resistance after failure of WHO recommended fi rst-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. Lancet Infect Dis. 2016;16:565\u201375.","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"3400_CR29","doi-asserted-by":"publisher","first-page":"e79981","DOI":"10.1371\/journal.pone.0079981","volume":"8","author":"N Ford","year":"2013","unstructured":"Ford N, Shubber Z, Hill A, et al. Comparative efficacy of lamivudine and Emtricitabine: a systematic review and meta-analysis of randomized trials. PLoS One. 2013;8(11):e79981.","journal-title":"PLoS One"},{"issue":"1","key":"3400_CR30","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1093\/cid\/cir728","volume":"54","author":"V Von Wyl","year":"2012","unstructured":"Von Wyl V, Yerly S, B\u00f6ni J, et al. Swiss HIV cohort study. Incidence of HIV-1 drug resistance among antiretroviral treatment-naive individuals starting modern therapy combinations. Clin Infect Dis. 2012;54(1):131\u201340.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"3400_CR31","doi-asserted-by":"publisher","first-page":"e67188","DOI":"10.1371\/journal.pone.0067188","volume":"8","author":"GU Van Zyl","year":"2013","unstructured":"Van Zyl GU, Liu TF, Claassen M, Engelbrecht S, et al. Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in south African patients receiving first and second-line antiretroviral treatment regimens. PLoS One. 2013;8(6):e67188.","journal-title":"PLoS One"},{"issue":"5","key":"3400_CR32","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1097\/QAI.0b013e3181ba1b00","volume":"52","author":"WS Stevens","year":"2009","unstructured":"Stevens WS, Wallis CL, Sanne I, Venter F. Will etravirine work in patients failing nonnucleoside reverse transcriptase inhibitor-based treatment in southern Africa? J Acquir Immune Defic Syndr. 2009;52(5):655\u20136.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"3400_CR33","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.jcv.2010.01.018","volume":"47","author":"S Kiertiburanakul","year":"2010","unstructured":"Kiertiburanakul S, Wiboonchutikul S, Sukasem C, Chantratita W, Sungkanu- parph S. Using of nevirapine is associated with intermediate and reduced response to etravirine among HIV-infected patients who experienced virologic failure in a resource- limited setting. J Clin Virol. 2010;47(4):330\u20134.","journal-title":"J Clin Virol"},{"issue":"3","key":"3400_CR34","doi-asserted-by":"publisher","first-page":"194","DOI":"10.2174\/157016210791111098","volume":"8","author":"B Taiwo","year":"2010","unstructured":"Taiwo B, Chaplin B, Penugonda S, et al. Suboptimal Etravirine activity is common during failure of Nevirapine-based combination antiretroviral therapy in a cohort infected with non-B subtype HIV-1. Curr HIV Res. 2010;8(3):194\u20138.","journal-title":"Curr HIV Res"},{"key":"3400_CR35","unstructured":"Paton, N, Kityo, C, Thompson, J, et al. Impact of NRTI cross-resistance on second-line PI + NRTI therapy outcomes in Africa; Conference on Retrovirus and Opportunistic Infections; Seattle, WA, USA. Feb 23\u201326, 2015;119 (abstr)."},{"key":"3400_CR36","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1089\/aid.2015.0331","volume":"32","author":"EP Lam","year":"2016","unstructured":"Lam EP, Moore CL, Gotuzzo E, et al. Antiretroviral resistance ater first-line anti- retroviral therapy failure in diverse HIV-1 subtypes in the SECOND-LINE study. AIDS Res Hum Retrovir. 2016;32:841\u201350.","journal-title":"AIDS Res Hum Retrovir"},{"issue":"5","key":"3400_CR37","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1086\/604731","volume":"200","author":"A Cozzi-Lepri","year":"2009","unstructured":"Cozzi-Lepri A, Phillips AN, Martinez-Picado J, et al. EuroSIDA study group. Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings. J Infect Dis. 2009;200(5):687\u201397.","journal-title":"J Infect Dis"},{"key":"3400_CR38","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/QAI.0b013e3181359cfb","volume":"46","author":"JM Molina","year":"2007","unstructured":"Molina JM, Cohen C, Katlama C, Grinsztejn B, Timerman A, Pedro RD. et al.Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment- experienced patients: 24-week results of POWER 3. J Acquir Immune Defic Syndr. 2007;46:24\u201331.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"3400_CR39","doi-asserted-by":"crossref","unstructured":"Grinsztejn B, Nguyen B-Y, Katlama C, et al. For the Protocol 005Team. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment- experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet. 2007;369:1261\u20139.","DOI":"10.1016\/S0140-6736(07)60597-2"},{"issue":"2","key":"3400_CR40","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.bjid.2016.11.009","volume":"21","author":"H Duani","year":"2017","unstructured":"Duani H, Aleixo AW, Tupinamb\u00e1s U. Trends and predictors of HIV-1 acquired drug resistance in Minas Gerais, Brazil: 2002-2012. Braz J Infect Dis. 2017;21(2):148\u201354.","journal-title":"Braz J Infect Dis"},{"key":"3400_CR41","unstructured":"Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial."},{"key":"3400_CR42","unstructured":"Horizons\/Population Council, International Centre for Reproductive Health and Coast Province General Hospital, Mombasa-Kenya. Adherence to Antiretroviral Therapy in Adults: A Guide for Trainers. Nairobi: Population Council. 2004. Available from: http:\/\/www.popcouncil.org\/uploads\/pdfs\/horizons\/mombasaarvtrainingguide.pdf . Accessed 6 Feb 2018."},{"key":"3400_CR43","first-page":"109","volume":"6","author":"R Shigdel","year":"2014","unstructured":"Shigdel R, Klouman E, Bhandari A, et al. Factors associated with adherence to antiretroviral therapy in HIV-infected patients in Kathmandu District, Nepal. HIV AIDS (Auckl). 2014;6:109\u201316.","journal-title":"HIV AIDS (Auckl)"},{"issue":"3","key":"3400_CR44","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/QAD.0000000000000544","volume":"29","author":"MA Vandenhende","year":"2015","unstructured":"Vandenhende MA, Ingle S, May M, et al. Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients: the antiretroviral therapy cohort collaboration (ART-CC). AIDS. 2015;29(3):373\u201383.","journal-title":"AIDS"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-018-3400-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-018-3400-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-018-3400-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T22:26:42Z","timestamp":1662244002000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-018-3400-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,12]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["3400"],"URL":"https:\/\/doi.org\/10.1186\/s12879-018-3400-6","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,12]]},"assertion":[{"value":"28 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was submitted and approved by the ethics committee of Federal University of Pernambuco for the publication of this work. The informed consent was not obtained from all participants because it was waived by the ethics committee of Federal University of Pernambuco. Furthermore, the data was also de-identified. A copy of the written consent by ethics committee of Federal University of Pernambuco is available for review by the editor-in-chief of this journal. The authors declare that the procedures followed the regulations established by the local ethics committee of Federal University of Pernambuco and the helsinki declaration of the world medical association. Federal University of Pernambuco gave access to confidential patient medical records to the authors and these records were anonymous.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declared no potential competing interest with respect to the research, authorship, and\/or publication of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"514"}}